A Blood-Based Prognostic Liver Secretome Signature and Long-Term Hepatocellular Carcinoma Risk in Advanced Liver Fibrosis
- 1 January 2021
- preprint
- Published by Elsevier BV in SSRN Electronic Journal
Abstract
Background: Accurate non-invasive prediction of long-term hepatocellular carcinoma (HCC) risk in advanced liver fibrosis is urgently needed for cost-effective HCC screening; however, this currently remains an unmet need. Methods: A serum-protein-based prognostic liver secretome signature (PLSec) was bioinformatically derived from previously validated hepatic transcriptome signatures and optimized in 79 patients with advanced liver fibrosis. We independently validated PLSec for HCC risk in 331 cirrhosis patients with mixed etiologies (validation set 1 [V1], median follow-up 4.5 years) and thereafter developed a composite risk score including clinical prognostic variables. The score was then validated in two independent cohorts: validation set 2 (V2): 164 patients with advanced liver fibrosis due to hepatitis C virus (HCV) infection cured after direct-acting antiviral therapy (nested case-control series, median follow-up 4.5 years); validation set 3 (V3): 146 patients with advanced liver fibrosis with successfully-treated HCC and cured HCV infection (median follow-up 2.9 years). Findings: An 8-protein blood-based PLSec recapitulated transcriptome-based hepatic HCC risk status. In V1, PLSec was significantly associated with incident HCC risk (adjusted hazard ratio [aHR], 2.35; 95% confidence interval [CI], 1.30-4.23). A composite score with serum alpha-fetoprotein (PLSec-AFP) was defined in V1, and validated in V2 (adjusted odds ratio, 3.80 [95%CI, 1.66-8.66]) and V3 (aHR, 3.08 [95%CI, 1.78-5.31]; c-index, 0.74). PLSec-AFP outperformed AFP alone (Brier score, 0.165 vs. 0.186 in V2; 0.196 vs. 0.206 in V3, respectively). Conclusions: The blood-based PLSec-AFP can accurately stratify patients with advanced liver fibrosis for long-term HCC risk and thereby guide risk-based tailored HCC screening.This publication has 78 references indexed in Scilit:
- Estimating the Receiver Operating Characteristic Curve in Studies That Match Controls to Cases on CovariatesAcademic Radiology, 2013
- Principled missing data methods for researchersSpringerPlus, 2013
- Odds and Odds RatioPublished by Springer Science and Business Media LLC ,2011
- A Unique Metastasis Gene Signature Enables Prediction of Tumor Relapse in Early-Stage Hepatocellular Carcinoma PatientsCancer Research, 2010
- Cancer Biomarkers: Can We Turn Recent Failures into Success?JNCI Journal of the National Cancer Institute, 2010
- Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinomaMolecular Cancer, 2010
- Identifying Genes for Establishing a Multigenic Test for Hepatocellular Carcinoma Surveillance in Hepatitis C Virus-Positive Cirrhotic PatientsCancer Epidemiology, Biomarkers & Prevention, 2009
- Gene Expression in Fixed Tissues and Outcome in Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- Maximally Selected Rank StatisticsBiometrics, 1992